exRNAdisease

General Information

Database ID:

exR0087695

RNA Name:

hsa-miR-1270

RNA Type:

miRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

20399320

End Site(bp):

20399342

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
MIEF1	chr22	39499432	39518132	+
WIPF2	chr17	40219304	40284136	+
GBA2	chr9	35736866	35749228	-
HIF1AN	chr10	100529072	100559998	+
TCF12	chr15	56918623	57299281	+
CDC42EP2	chr11	65314866	65322417	+
LITAF	chr16	11547722	11636381	-
GRHL2	chr8	101492439	101669726	+
PRLR	chr5	35048756	35230487	-
PATL1	chr11	59636716	59669037	-
CACNG4	chr17	66964707	67033398	+
ZNF652	chr17	49289206	49362473	-
CDC37	chr19	10391133	10420121	-
AGFG1	chr2	227472152	227561214	+
SMG7	chr1	183472216	183598246	+
TRIP6	chr7	100867387	100873454	+
FN1	chr2	215360440	215436073	-
DCBLD2	chr3	98795941	98901695	-
BEND3	chr6	107065182	107115269	-
NACC1	chr19	13116862	13141147	+
TPM4	chr19	16067021	16103002	+
TLNRD1	chr15	81000923	81005788	+
SRGAP2	chr1	206203345	206464443	+
PITPNA	chr17	1517718	1562792	-
FAM78A	chr9	131258076	131276510	-
ATP6V1B2	chr8	20197381	20226819	+
VGF	chr7	101162509	101165569	-
PLAGL2	chr20	32192504	32207743	-
PCDH10	chr4	133149294	133208606	+
B4GALT5	chr20	49632945	49713878	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001247	chr22	46125304	46136418	+
hsa_circ_0001159	chr20	40161688	40179999	-
hsa_circ_0000471	chr13	33091993	33101669	-
hsa_circ_0001666	chr6	170626457	170639638	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC239868.1	chr1	149861271	149862504	+
AC245033.4	chr15	82533175	82540008	-
AP000233.2	chr21	25095022	25103670	+
MALAT1	chr11	65497688	65506516	+
NEAT1	chr11	65422774	65445540	+
NORAD	chr20	36045618	36051018	-
NR2F2-AS1	chr15	96110040	96327361	-
OIP5-AS1	chr15	41283990	41309737	+
SNHG12	chr1	28578538	28583132	-
SNHG8	chr4	118278709	118285316	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.